Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.
Novo Nordisk has reported strong revenue and profit growth over the past five years. The company recently upgraded its guidance for 2023.
Novo Nordisk's Ozempic to take center stage when the pharma giant reports 3Q earnings next week
Novo Nordisk (NYSE:NVO) is scheduled to report earnings on November 2 before the opening bell The Street consensus for Novo Nordisk (NYSE:NVO) is earnings of $0.71 per share on revenue of $7.91 bil...
Novo Nordisk Milks The Obesity Cash Cow - How Long Will It Last?
NVO's obesity/diabetes drug, Wegovy/Ozempic, is projected to outperform the best-selling drug of all time, Humira, with an estimated $38.5B in annual sales by 2030. This has led to the stock's infl...
Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
Novo Nordisk stock has tripled since 2020 and is up over 30% YTD; but there is still upside. Novo is poised to benefit from the surging demand for diabetes and obesity care, with an estimated annua...
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
The latest trading day saw Novo Nordisk (NVO) settling at $97.12, representing a +0.86% change from its previous close.
Ozempic Maker Novo Nordisk Has a Weight Problem
What happens when one company accounts for more than half of a stock index?
The $100 billion dollar opportunity in obesity drugs, Goldman Sachs analyst explains
A Goldman Sachs report predicts that the total addressable market for weight loss drugs could reach $100 billion dollars by 2030. Popular weight loss drugs like Novo Nordisk's Ozempic (NVO) have pi...
Options Traders Oh-Oh-Overjoyed With This Ozempic Trade
Subscribers to Chart of the Week received this commentary on Sunday, October 15.
Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B
Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
Novo Nordisk (NVO) closed at $101.15 in the latest trading session, marking a -0.97% move from the prior day.
Novo Nordisk buys blood pressure treatment to bolster diabtetes portfolio
Novo Nordisk (NYSE:NVO) has agreed to buy ocedurenone, a blood pressure drug for with potential applications in cardiovascular and kidney disease, the Danish group said today. Buoyed by the success...
Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain
Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.
Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 Billion—Expanding Ozempic Maker's Arsenal
The Danish firm said the drug has “best-in-class potential” for treating uncontrolled hypertension.
Novo Nordisk Buys Hypertension Drug in $1.3 Billion Deal
Novo Nordisk (NVO) agreed to buy ocedurenone, a drug that treats uncontrolled hypertension and has the potential to be used in cases of cardiovascular and kidney disease, from KBP Biosciences for u...
Novo Nordisk in $1.3 bln deal to buy hypertension drug
Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Da...
Related Companies